We are live on
!
Find out more
EFM
E Fund Management Portfolio holdings
AUM
$3.37B
This Fund
S&P 500
This Quarter
Est. Return
+12.44%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.31B
AUM Growth
+$49.5M
(+3.9%)
Cap. Flow
-$34.5M
Cap. Flow
% of AUM
-2.63%
Top 10 Holdings %
Top 10 Hldgs %
65.03%
Holding
329
New
20
Increased
146
Reduced
123
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KLA
KLAC
|
+$10.2M |
| 2 |
Pinduoduo
PDD
|
+$7.52M |
| 3 |
iShares MSCI Global Gold Miners ETF
RING
|
+$3.39M |
| 4 |
iShares Gold Trust
IAU
|
+$3.38M |
| 5 |
SPDR Gold MiniShares Trust
GLDM
|
+$3.27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Grab
GRAB
|
+$40.9M |
| 2 |
NVIDIA
NVDA
|
+$7.7M |
| 3 |
Microsoft
MSFT
|
+$6.02M |
| 4 |
STAAR Surgical
STAA
|
+$5.62M |
| 5 |
Sea Limited
SE
|
+$3.76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 45.37% |
| 2 | Technology | 25.37% |
| 3 | Communication Services | 8.93% |
| 4 | Healthcare | 6.43% |
| 5 | Real Estate | 6.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Boston Scientific
BSX
$68.3B
| $207K | 0.02% |
3,924
-302
| -7% | -$15.8K |
|
252
Geron
GERN
$949M
| $207K | 0.02% |
97,708
+26,473
| +37% | +$71.8K |
|
253
Zentalis Pharmaceuticals
ZNTL
$323M
| $207K | 0.02% |
10,307
-3,185
| -24% | -$80.8K |
|
254
Viridian Therapeutics
VRDN
$2.17B
| $206K | 0.02% |
13,437
+315
| +2% | +$6.01K |
|
|
WBA
255
DELISTED
Walgreens Boots Alliance
WBA
| $206K | 0.02% |
9,263
+1,412
| +18% | +$37.5K |
|
|
BLUE
256
DELISTED
bluebird bio
BLUE
| $204K | 0.02% |
3,349
-1,081
| -24% | -$75.9K |
|
257
Hewlett Packard
HPE
$62.6B
| $204K | 0.02% |
11,726
-914
| -7% | -$15.7K |
|
258
Becton Dickinson
BDX
$43.8B
| $203K | 0.02% |
784
-65
| -8% | -$17.6K |
|
259
HP
HPQ
$24.1B
| $202K | 0.02% |
7,878
-589
| -7% | -$18.1K |
|
260
Monolithic Power Systems
MPWR
$65.1B
| $201K | 0.02% |
435
-8
| -2% | -$4.09K |
|
261
Editas Medicine
EDIT
$413M
| $199K | 0.02% |
25,455
-5,468
| -18% | -$46.9K |
|
|
VERV
262
DELISTED
Verve Therapeutics
VERV
| $191K | 0.01% |
14,397
+1,499
| +12% | +$24.1K |
|
263
MannKind Corp
MNKD
$1.26B
| $182K | 0.01% |
43,955
-19,726
| -31% | -$88.6K |
|
264
Myriad Genetics
MYGN
$530M
| $172K | 0.01% |
10,709
+159
| +2% | +$3.03K |
|
265
Coherus Oncology
CHRS
$224M
| $168K | 0.01% |
+45,010
| New | +$208K |
|
266
AT&T
T
$166B
| $168K | 0.01% |
11,172
-767
| -6% | -$11.2K |
|
267
Travere Therapeutics
TVTX
$5.38B
| $166K | 0.01% |
18,596
-8,198
| -31% | -$116K |
|
268
Biomea Fusion
BMEA
$92.5M
| $165K | 0.01% |
+12,010
| New | +$217K |
|
269
SiriusXM
SIRI
$10.5B
| $164K | 0.01% |
3,625
+652
| +22% | +$30.3K |
|
270
Relay Therapeutics
RLAY
$4.1B
| $163K | 0.01% |
19,403
-14,305
| -42% | -$154K |
|
|
DAWN
271
DELISTED
Day One Biopharmaceuticals
DAWN
| $149K | 0.01% |
12,176
-3,465
| -22% | -$45.2K |
|
272
uniQure
QURE
$2.66B
| $135K | 0.01% |
20,075
+9,422
| +88% | +$84.8K |
|
273
Allogene Therapeutics
ALLO
$621M
| $128K | 0.01% |
40,325
-736
| -2% | -$3.23K |
|
274
Caribou Biosciences
CRBU
$161M
| $125K | 0.01% |
+26,065
| New | +$162K |
|
275
Lucid Motors
LCID
$2.54B
| $120K | 0.01% |
2,144
+734
| +52% | +$47.5K |
|
Similar funds
VFCM
DFO
DIA
5NCM
TAM
CS
OAM
QCG
E Fund Management's Q3 2023 Portfolio in Review
As of Q3 2023, E Fund Management held 329 positions worth $1.31B, up 3.9% from $1.26B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
E Fund Management's Q3 2023 filing shows 20 new, 146 increased, 123 reduced and 37 closed positions. Its largest new stake was iShares MSCI Global Gold Miners ETF: 148,564 shares worth $3.08M. The largest sale was Grab, an estimated $40.9M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 45% of assets, up from 37% a quarter earlier, followed by Technology and Communication Services.
- E Fund Management's largest Q3 2023 buy was iShares MSCI Global Gold Miners ETF: 148,564 shares worth $3.08M.
- E Fund Management added most to KLA in Q3 2023, an estimated $10.2M increase.
- E Fund Management's biggest Q3 2023 reduction was NVIDIA, cutting an estimated $7.7M.
- E Fund Management fully exited Grab in Q3 2023, selling an estimated $40.9M.
- E Fund Management's ten largest holdings make up 65% of its $1.31B portfolio in Q3 2023.
- E Fund Management opened 20 new positions and closed 37 in Q3 2023.
- E Fund Management's portfolio value rose 3.9% quarter-over-quarter to $1.31B.
Based on E Fund Management's 13F filing for Q3 2023, filed 13 Nov 2023.